Please login to the form below
acute myeloid leukemia
This page shows the latest acute myeloid leukemia news and features for those working in and with pharma, biotech and healthcare.
FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments
for patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and AML patients unable to receive intensive chemotherapy. ... Speaking on the company’s commitment to developing new MDS therapies, Parsey said: “Considering the high
Latest news
-
BMS’s oral AML therapy Onureg receives EU approval
The European Commission has granted Bristol Myers Squibb’s (BMS) Onureg a full marketing authorisation as maintenance therapy for adult patients with acute myeloid leukaemia (AML). ... Today’s approval of Onureg represents a significant advance for
-
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
bluebird bio has announced that a recently reported suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukemia (AML) is "very unlikely" to be related to its sickle cell disease (SCD)
-
Astellas’ Xospata scores positive CHMP recommendation
The FLT3 inhibitor received the positive opinion for use as a monotherapy in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation. ... 2017. AML is the most common form of acute leukaemia in adults and has a low
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
UCART123 is a gene-edited CAR-T cell therapy that targets CD123 and will be tested in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
-
Pfizer's SMO inhibitor boosts survival in blood cancer trial
Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) to almost nine months when added to low-dose ... indications such as MDS, acute lymphoblastic
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest from PMHub
-
Acute leukaemia patients get new online information centre that will help them get the best possible care
a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most. ... Some of the world's leading experts in the treatment of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- OPEN Health and Nested Knowledge announce strategic research collaboration to leverage AI technologies for evidence synthesis
- FDA approves two cell-based gene therapies for sickle cell disease
- Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma
- New economic data reveals risk of disincentivising UK life sciences growth
- WHO countries hold seventh INB meeting to prevent global pandemics
- The start of a beautiful friendship
No results were found
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
- Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
